MX2019006278A - Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. - Google Patents

Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.

Info

Publication number
MX2019006278A
MX2019006278A MX2019006278A MX2019006278A MX2019006278A MX 2019006278 A MX2019006278 A MX 2019006278A MX 2019006278 A MX2019006278 A MX 2019006278A MX 2019006278 A MX2019006278 A MX 2019006278A MX 2019006278 A MX2019006278 A MX 2019006278A
Authority
MX
Mexico
Prior art keywords
health
offspring
nad precursors
improving maternal
nad
Prior art date
Application number
MX2019006278A
Other languages
English (en)
Inventor
M Brenner Charles
Hien Ear Po
Chadda Ankita
Migaud Marie
Stevens Hanna
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of MX2019006278A publication Critical patent/MX2019006278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Ciertas modalidades de la invención proporcionan un método para mejorar salud materna y/o de la descendencia, que comprende administrar una cantidad efectiva de un precursor de dinucleótido de nicotinamida adenina (NAD) a un mamífero hembra (por ejemplo, mamífero hembra embarazada o lactante).
MX2019006278A 2016-11-29 2017-11-29 Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. MX2019006278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427661P 2016-11-29 2016-11-29
PCT/US2017/063733 WO2018102426A1 (en) 2016-11-29 2017-11-29 Use of nad precursors for improving maternal health and/or offspring health

Publications (1)

Publication Number Publication Date
MX2019006278A true MX2019006278A (es) 2019-08-21

Family

ID=62242630

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006278A MX2019006278A (es) 2016-11-29 2017-11-29 Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.

Country Status (9)

Country Link
US (1) US11633421B2 (es)
EP (1) EP3554285A4 (es)
JP (1) JP7136795B2 (es)
CN (1) CN110234238B (es)
AU (1) AU2017367092B2 (es)
BR (1) BR112019010607B1 (es)
CA (1) CA3044814A1 (es)
MX (1) MX2019006278A (es)
WO (1) WO2018102426A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
CA3044814A1 (en) 2016-11-29 2018-06-07 Charles M. Brenner Use of nad precursors for improving maternal health and/or offspring health
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
EP3975746A4 (en) * 2019-05-31 2023-05-31 Nutriquest, LLC THERAPEUTIC CLAY COMPOSITIONS AND METHOD OF USE

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH318073A (de) 1953-07-17 1956-12-15 Hoffmann La Roche Verfahren zur Herstellung von Nicotinsäureabkömmlingen
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5055460A (en) 1990-04-26 1991-10-08 Mitchell Friedlander Method for weight loss
EP0967984A1 (en) 1997-03-04 2000-01-05 Peregrine Pharmaceutical, Inc. Composition and method for treating cancer and immunological disorders resulting in chronic conditions
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
US6624150B2 (en) 1999-02-26 2003-09-23 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US20040224918A1 (en) 2000-07-11 2004-11-11 Yatvin Milton B. Anti-mycobacterial compounds
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP2236131A3 (en) 2003-07-01 2011-03-02 President and Fellows of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
US20050227327A1 (en) 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
ES2663226T3 (es) 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP1957086B1 (en) 2005-11-18 2018-05-02 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
US20080318892A1 (en) 2006-04-28 2008-12-25 John Geoffrey Pickering Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US20090196942A1 (en) 2008-02-01 2009-08-06 Goyarts Earl C Topical compositions containing citrus jabara extract
US9790252B2 (en) 2009-07-01 2017-10-17 Cornell University 2-fluorinated riboses and arabinoses and methods of use and synthesis
US9603862B2 (en) 2009-12-14 2017-03-28 Cornell University Activation and activators of SIRT5
US20130165398A1 (en) 2010-03-29 2013-06-27 Paul Hochegger Concentration-enhancing drink
WO2012162796A1 (en) * 2011-05-31 2012-12-06 Queen's University At Kingston Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure and restoring glucose tolerance
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
CA2847292A1 (en) * 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US8183227B1 (en) * 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
EP2574339A1 (de) 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
CN110051672A (zh) 2012-07-09 2019-07-26 诺格罗有限责任公司 使用膳食补充剂预防酒精反应
WO2014014828A1 (en) 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
WO2014059031A2 (en) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors in the prevention and treatment of inflammation
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
CA2919428A1 (en) * 2013-07-30 2015-02-05 Benemilk Oy Feed for lactating ruminants
EP3063163B1 (en) 2013-10-30 2022-08-10 Chromadex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
JP2017518306A (ja) 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
AU2015283905B2 (en) * 2014-07-03 2020-10-22 NAN Global, LLC Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes
ES2908332T3 (es) 2014-07-24 2022-04-28 Grace W R & Co Forma cristalina de cloruro de ribosilnicotinamida
WO2016049236A1 (en) 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
EP3242675B1 (en) * 2015-01-05 2022-11-30 Cornell University Compositions and methods using il-8 to improve milk production and reproductive health in mammals
ES2963057T3 (es) 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
BR112017019696A2 (pt) 2015-03-16 2018-09-04 ChromaDex Inc. composto e usos de um composto
US20180071273A1 (en) * 2015-03-17 2018-03-15 Speccialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
JP2018517709A (ja) 2015-06-04 2018-07-05 クロマデックス, インコーポレイテッドChromaDex, Inc. 選択的な無溶媒リン酸化
KR101604212B1 (ko) 2015-07-17 2016-03-17 울산대학교 산학협력단 Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
AU2017232930B2 (en) 2016-03-16 2021-03-25 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
CN115176998A (zh) * 2016-04-14 2022-10-14 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸和烟碱基化合物衍生物在婴儿配方中的用途
MX2018012849A (es) 2016-04-20 2019-08-29 Chromadex Inc Uso de derivados de ribósido de ácido nocotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores de que incementan nad+.
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
CA3044814A1 (en) 2016-11-29 2018-06-07 Charles M. Brenner Use of nad precursors for improving maternal health and/or offspring health
WO2018200357A1 (en) * 2017-04-26 2018-11-01 Elysium Health, Inc. Methods and compositions of improving fertility
CN111315867A (zh) * 2017-06-30 2020-06-19 益力舒健康公司 合成烟酰胺核苷的方法

Also Published As

Publication number Publication date
WO2018102426A1 (en) 2018-06-07
US11633421B2 (en) 2023-04-25
US20210106606A1 (en) 2021-04-15
JP7136795B2 (ja) 2022-09-13
CN110234238A (zh) 2019-09-13
CA3044814A1 (en) 2018-06-07
AU2017367092A1 (en) 2019-06-20
BR112019010607B1 (pt) 2023-10-31
CN110234238B (zh) 2023-03-28
EP3554285A1 (en) 2019-10-23
BR112019010607A2 (pt) 2019-09-17
JP2020504168A (ja) 2020-02-06
AU2017367092B2 (en) 2022-11-03
EP3554285A4 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
MX2019006278A (es) Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
MX2017014787A (es) Poblaciones bacterianas para promover la salud.
ZA201807736B (en) Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12015502788A1 (en) Antibody formulations and methods
MX2016013133A (es) Composicion que contiene peroxido y agente antimicrobiano y proceso de matar esporas.
IN2015DN01156A (es)
EP3907283A3 (en) Buffers for stabilization of lentiviral preparations
MX2017008669A (es) Metodos de transdiferenciacion y metodos de uso de esta.
PH12017500933A1 (en) Sublingual administration of riluzole
PH12017500934A1 (en) Sublingual formulation of riluzole
MX2018001849A (es) Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo.
PH12017501692A1 (en) Solid forms of menaquinols
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX2016012890A (es) Reduccion de concentracion inhibitoria minima (mic) con iones litio.
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
MX2020011946A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
IN2015DN03761A (es)
MX2015012043A (es) Agonistas muscarinicos.
WO2014144731A3 (en) Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
MX2019008535A (es) Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.
SG10201806381VA (en) Treatment of h. pylori infections using mtan inhibitors